Tao Xie, MD, PhD, specializes in the diagnosis and treatment of various movement disorders, including Parkinson's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), cortical basal ganglionic degeneration (CBGD), Huntington's disease (HD) and chorea, tremor, dystonia, hemifacial spasm, blepharospasm, tics, and Tourette syndrome. He uses medications, botulinum toxin injection and deep brain stimulation surgery for treatment of these neurological conditions.
In his clinical research, Dr. Xie studies the effectiveness of deep brain stimulation for the treatment of various movement disorders. He is also actively involved in clinical trials and research in Parkinson’s disease, PSP, MSA and tremor, and also the role of the DatScan in movement disorders.
Dr. Xie is a physician in the University of Chicago Center for Parkinson's Disease and Movement Disorders. Dedicated as a Center for Advanced Research by the American Parkinson Disease Association, this multidisciplinary center combines clinical expertise with state-of-the-art therapies and groundbreaking research.
Columbia University Medical Center
NY
Fellowship - Movement Disorders
Emory University School of Medicine
GA
Residency - Neurology
Emory University School of Medicine
GA
Internship - Medicine
Johns Hopkins School of Medicine
MD
Research - Neurology
The University of Hong Kong
Ph.D. - Parkinson's Disease
Zhejiang University School of Medicine
China
MD
Survey of common deep brain stimulation programming practices by experts in Parkinson's Disease.
Survey of common deep brain stimulation programming practices by experts in Parkinson's Disease. J Neurol. 2024 Dec 12; 272(1):49.
PMID: 39666124
Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy.
Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy. Front Neurol. 2024; 15:1501206.
PMID: 39777317
The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol.
The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol. BMC Neurol. 2024 Oct 21; 24(1):403.
PMID: 39434044
Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B).
Clinical, Radiological and Pathological Features of a Large American Cohort of Spinocerebellar Ataxia (SCA27B). Ann Neurol. 2024 Dec; 96(6):1092-1103.
PMID: 39263992
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials. Mov Disord. 2024 Aug; 39(8):1329-1342.
PMID: 38825840
Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease". Mov Disord. 2024 Apr; 39(4):760-761.
PMID: 38661038
GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians. Mov Disord. 2024 Apr; 39(4):728-733.
PMID: 38390630
Cognitive outcomes in patients with essential tremor treated with deep brain stimulation: a systematic review.
Cognitive outcomes in patients with essential tremor treated with deep brain stimulation: a systematic review. Front Hum Neurosci. 2024; 18:1319520.
PMID: 38371461
Multi-ancestry genome-wide association meta-analysis of Parkinson's disease.
Multi-ancestry genome-wide association meta-analysis of Parkinson's disease. Nat Genet. 2024 Jan; 56(1):27-36.
PMID: 38155330
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2023 Nov; 29(11):2955-2956.
PMID: 36253611